Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 20;16(8):1354-1364.
doi: 10.1021/acschembio.1c00094. Epub 2021 Jul 12.

Identifying the Cellular Target of Cordyheptapeptide A and Synthetic Derivatives

Affiliations

Identifying the Cellular Target of Cordyheptapeptide A and Synthetic Derivatives

Victoria G Klein et al. ACS Chem Biol. .

Abstract

Cordyheptapeptide A is a lipophilic cyclic peptide from the prized Cordyceps fungal genus that shows potent cytotoxicity in multiple cancer cell lines. To better understand the bioactivity and physicochemical properties of cordyheptapeptide A with the ultimate goal of identifying its cellular target, we developed a solid-phase synthesis of this multiply N-methylated cyclic heptapeptide which enabled rapid access to both side chain- and backbone-modified derivatives. Removal of one of the backbone amide N-methyl (N-Me) groups maintained bioactivity, while membrane permeability was also preserved due to the formation of a new intramolecular hydrogen bond in a low dielectric solvent. Based on its cytotoxicity profile in the NCI-60 cell line panel, as well as its phenotype in a microscopy-based cytological assay, we hypothesized that cordyheptapeptide was acting on cells as a protein synthesis inhibitor. Further studies revealed the molecular target of cordyheptapeptide A to be the eukaryotic translation elongation factor 1A (eEF1A), a target shared by other lipophilic cyclic peptide natural products. This work offers a strategy to study and improve cyclic peptide natural products while highlighting the ability of these lipophilic compounds to effectively inhibit intracellular disease targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Compound structures a) chemical structure of cordyheptapeptide A (1). b) Effect of 1 on cell proliferation in HCT 116 cells after 72 h. Error bars are one SD. N =3
Figure 2
Figure 2
Molecular dynamics results comparing cordyheptapeptide A (1) and 11 a – b) Principal component (PC) analysis of free energy landscapes in chloroform (CHCl3) and water (H2O) for a) 1 and b) 11. The triangle in cyan labeled with “A” denotes the mirror-imaged X-ray structure (CCDC 287376). Green numbers within each plot indicate representative structures in each solvent. c) Major MD simulated conformer of 1 in chloroform. d) Overlay of the major conformer in water for 1 (in green) and 11 (in purple). e) Major MD simulated conformer of 11 in chloroform.
Figure 3
Figure 3
COMPARE results and cytological profiling dendrogram fingerprint a) Top ten compounds with known MOA, - from COMPARE analysis ordered by COMPARE correlation to 1 b) Cytological profiling results of 1 compared to DMSO controls, normalized with features represented on a scale from −1 (blue, below DMSO control) to +1 (yellow, above DMSO control) with black indicating no difference between compound and DMSO for that feature.
Figure 4
Figure 4
Effects of cordyheptapeptide A on protein synthesis and DNA synthesis a – b) Representative images of HeLa cells stained for the following features: nuclei (Hoechst, blue), protein synthesis (BONCAT, green) after a 24-h incubation with a) DMSO orb) 100 nM 1. c) Effect of 1 on normalized cell average BONCAT intensity in HeLa cells. d – e) Representative images of HeLa cells stained for the following features: nuclei (Hoechst, blue), and S-phase cells (EdU, yellow) d) DMSO or e) 0.6 μM 1. f) Effect of 1 on normalized EdU intensity in HeLa cells. Scale bars: 211 μm. Error bars are one SD.
Figure 5
Figure 5. Target identification
eEF1A WT HCT 116 cells and eEF1A A399V HCT 116 cells were incubated with 1 for 72 hours. Cell proliferation was measured with and Alamar blue assay. Error bars are one SD.

Similar articles

Cited by

References

    1. Bockus AT; McEwen CM; Lokey RS, Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective. Curr. Top. Med. Chem 2013, 13 (7), 821–836. - PubMed
    1. Zorzi A; Deyle K; Heinis C, Cyclic Peptide Therapeutics: Past, Present and Future. Curr. Opin. Chem. Biol 2017, 38, 24–29. - PubMed
    1. Pye CR; Bertin MJ; Lokey RS; Gerwick WH; Linington RG, Retrospective Analysis of Natural Products Provides Insights for Future Discovery Trends. Proc. Natl. Acad. Sci 2017, 114 (22), 5601. - PMC - PubMed
    1. Marsault E; Peterson ML, Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery. J. Med. Chem 2011, 54 (7), 1961–2004. - PubMed
    1. Driggers EM; Hale SP; Lee J; Terrett NK, The Exploration of Macrocycles for Drug Discovery - an Underexploited Structural Class. Nat. Rev. Drug Discovery 2008, 7, 608–624. - PubMed

Publication types

MeSH terms